The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | S2303: nivolumab combo v paclitaxel + ramucirumab in PD-L1 CPS ≥ 1 gastric/esophageal adenocarcinoma
Anwaar Saeed, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses the rationale behind the Phase I/II PARAMMUNE trial (NCT06203600) (SWOG2303) investigating the efficacy and safety of nivolumab, paclitaxel, and ramucirumab compared to paclitaxel and ramucirumab in advanced stage MSS/pMMR PD-L1 CPS ≥ 1 gastric and esophageal adenocarcinoma. The trial is motivated by the promising results of the multi-center phase I/II trial that evaluated the addition of nivolumab to 2nd line ramucirumab plus paclitaxel. The study aims to explore the predictive impact of PD-L1 CPS and assess the primary endpoints of progression-free survival (PFS) in phase II and overall survival (OS) in Phase III. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
